CN104510717B - Olanzapine orally-disintegrating tablet and preparation method thereof - Google Patents
Olanzapine orally-disintegrating tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104510717B CN104510717B CN201310451237.7A CN201310451237A CN104510717B CN 104510717 B CN104510717 B CN 104510717B CN 201310451237 A CN201310451237 A CN 201310451237A CN 104510717 B CN104510717 B CN 104510717B
- Authority
- CN
- China
- Prior art keywords
- weight ratio
- olanzapine
- tablet
- mannitol
- crospovidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229960005017 olanzapine Drugs 0.000 title claims abstract description 39
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 27
- 239000003826 tablet Substances 0.000 claims abstract description 49
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 30
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 21
- 229930195725 Mannitol Natural products 0.000 claims abstract description 21
- 239000000594 mannitol Substances 0.000 claims abstract description 21
- 235000010355 mannitol Nutrition 0.000 claims abstract description 21
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960000913 crospovidone Drugs 0.000 claims abstract description 19
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 19
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 19
- 108010011485 Aspartame Proteins 0.000 claims abstract description 15
- 239000000605 aspartame Substances 0.000 claims abstract description 15
- 235000010357 aspartame Nutrition 0.000 claims abstract description 15
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 15
- 229960003438 aspartame Drugs 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 25
- 229960001855 mannitol Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 17
- 238000005516 engineering process Methods 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 239000000543 intermediate Substances 0.000 claims description 8
- 239000002075 main ingredient Substances 0.000 claims description 8
- 238000009702 powder compression Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 7
- 238000012545 processing Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 13
- 238000007873 sieving Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to olanzapine orally-disintegrating tablets and preparation method thereof.The disintegration time limited of the oral disintegrating tablet is less than or equal to 10 seconds, it includes: a) Olanzapine of 2% to 15% weight ratio；B) mannitol of 20% to 78% weight ratio；C) microcrystalline cellulose of 10% to 40% weight ratio；D) crospovidone of 1% to 20% weight ratio；E) aspartame of 0.2% to 5% weight ratio；And f) the magnesium stearate of 0.3% to 4% weight ratio.Olanzapine orally-disintegrating tablet of the invention shows as disintegration rate quickly from overall effect, and processing step is simple, at low cost, convenient to take, is suitable for extensive promotion and application.
Description
Technical field
The present invention relates to field of medicine preparations more particularly to olanzapine orally-disintegrating tablet and preparation method thereof.
Background technique
As the extension of average human life and age increase the decline of swallow, oral tablet administration mode becomes
A problem concerned by people.It is estimated that there are about 50% people to tablet is swallowed and capsule is had any problem, drug therapy is affected
Compliance.In paediatrics and old medicine, to can dissolve in water or suspend, can be chewed or can be dissolved rapidly in mouth
Solid pharmaceutical preparation has very big demand, then without the oral flash-dispersion formulations that can be dispersed or dissolved rapidly with water and swallowing act
This demand can be met.This dosage form can be dispersed or dissolved in saliva rapidly after being put into mouth, and drug can pass through oral cavity or food
Mucosal absorption in road, bioavilability is higher than ordinary preparation, and the side effect as caused by first-pass metabolism can also mitigate.
Oral disintegrating tablet, which refers to, is placed on lingual surface the one kind that can be disintegrated into countless particles and sweet mouthfeel in 30 seconds automatically newly
Type pharmaceutical preparation.It since its disintegration rate is fast, absorbs rapidly, and need not drink water after taking medicine, therefore be very suitable to some especial patients
(mental disease, senile dementia, epileptic patient etc.) and old man, child take.It is generallyd use when preparing oral disintegrating tablet both at home and abroad at present
Desivac, mechanography, direct compression method.
Olanzapine is suitable for the acute of schizophrenia and other mental diseases for having serious positive symptom and/or negative symptoms
Phase and the treatment for maintaining the phase, also can be relieved the secondary affective symptom of schizophrenia and related disease.This product is as novel anti-
Antipsychotic drugs have the advantages that long-term efficacy is good and Small side effects, obtain the highly recognition of clinician.
Compared with other technologies (such as desivac, compression moulding), the work of olanzapine orally-disintegrating tablet is prepared using direct tablet compressing technique
Skill is simpler, at low cost, is not required to special production equipment.Insoluble drug dissolution rate can be improved in the technology, usually with flowing
The preferable filler of property, adhesive and disintegrating agent, and it is aided with suitable lubricant and corrigent, mouth good in taste can be obtained and collapse
Piece.Existing direct tablet compressing technique is prepared in olanzapine orally-disintegrating tablet patent, and disintegration time limited is all larger than 10 seconds.
CN101904824 is disclosed " olanzapine orally-disintegrating tablet preparation and preparation method thereof ", selects mannitol and lactose joint
Using as filler, using 35%-74% mannitol and 10%-40% lactose as filler, the microcrystalline cellulose of 0%-10% is as dry
Adhesive, the disintegrating agent of 2%-10%, the corrigent of 0.1%-6%, the lubricant of 0.4%-3%, disintegration time limited was at 15 seconds to 45 seconds.
Aforementioned patents disclose olanzapine orally-disintegrating tablet preparation prescriptions and preparation method thereof, and are with direct powder compression work
Skill preparation, but it does not optimize screening to dry adhesives and disintegrating agent ratio, and disintegration time limited is long, patient medication compliance
Difference.
Summary of the invention
In order to solve the above-mentioned technical problems, the present invention provides a kind of olanzapine orally-disintegrating tablets and preparation method thereof.
Technical solution of the present invention is as follows: using mannitol as filler in prescription, microcrystalline cellulose as dry adhesives,
Crospovidone directly mixes pressure with Olanzapine as lubricant as corrigent, magnesium stearate as disintegrating agent, aspartame
Piece.
The present invention provides a kind of olanzapine orally-disintegrating tablet, disintegration time limited is less than or equal to 10 seconds.With weight ratio meter, it includes
Following ingredient:
A) Olanzapine of 2% to 15% weight ratio；
B) mannitol of 20% to 78% weight ratio；
C) microcrystalline cellulose of 10% to 40% weight ratio；
D) crospovidone of 1% to 20% weight ratio；
E) aspartame of 0.2% to 5% weight ratio；With
F) magnesium stearate of 0.3% to 4% weight ratio.
Wherein weight ratio is the ratio between each component and composition total weight.
Preferably, the oral disintegrating tablet includes:
A) Olanzapine of 3% to 12% weight ratio；
B) mannitol of 25% to 78% weight ratio；
C) microcrystalline cellulose of 12% to 35% weight ratio；
D) crospovidone of 3% to 12% weight ratio；
E) aspartame of 0.2% to 2% weight ratio；With
F) magnesium stearate of 0.5% to 3% weight ratio.
It is furthermore preferred that it is 25% to 78%, preferably 30% to 78% that mannitol, which accounts for the ratio of total weight of tablet, in the tablet.Institute
The particle diameter distribution for stating mannitol is preferably 50% partial size lower than 100 μm, and 90% partial size is lower than 250 μm.
Preferably, the ratio that microcrystalline cellulose accounts for total weight of tablet in the tablet is 12% to 35%, preferably 12% to 32%；
The microcrystalline cellulose particle diameter distribution is preferably 50% partial size lower than 150 μm, and 90% partial size is lower than 250 μm.Using such partial size
After can be preferably uniformly mixed with other auxiliary materials especially mannitol, to play the role of better molding.And inventor
It is surprised to find that it has significant impact to preparation disintegration time limited.
Further, the ratio that crospovidone accounts for total weight of tablet in the tablet is 3% to 12%, preferably 3% to 9%.
The crospovidone particle diameter distribution is preferably 50% partial size lower than 90 μm, and 90% partial size is lower than 150 μm.
Inventor has surprisingly found that by many experiments, when preparing olanzapine orally-disintegrating tablet using technique of direct powder compression,
Parteck deltaM is as filler, and as dry adhesives, crospovidone XL is used as to be collapsed microcrystalline cellulose PH102 or Type102
Agent is solved, had not only guaranteed that powder had good mobility and compressibility, but also guarantee that tablet has cracking disintegration time limited.
The object of the invention is also to provide a kind of methods for preparing the olanzapine orally-disintegrating tablet, and powder is used directly to press
Blade technolgy, the specific steps are as follows:
1) main ingredient Olanzapine and aspartame difference is finely ground, it sieves with 100 mesh sieve, weighs recipe quantity, the two is uniformly mixed；
2) by microcrystalline cellulose, crospovidone and mannitol respectively cross 60 meshes, weigh respectively according to quantity, and in order according to
In the secondary hybrid medicine being added in step 1), mix；
3) magnesium stearate of recipe quantity is added into hybrid medicine obtained in step 2, is sieved, mixes, carries out intermediate
Content detection, after determining slice weight, using the tabletting of direct tablet compressing technology to get.
The present invention is using mannitol as filler, and microcrystalline cellulose is as dry adhesives, and crospovidone is as disintegration
Agent, aspartame is as corrigent, and magnesium stearate is as lubricant, by above-mentioned specific preparation prescription, in conjunction with to each component
The screening of best prescription content, it is surprisingly found by the inventors that, the effect of Olanzapine Tablets of the present invention on the whole shows as disintegration rate
Quickly, good mouthfeel, the quality of the pharmaceutical preparations are stablized.
Commercially available olanzapine orally-disintegrating tablet is yellow freeze-drying tablet, and preparation process uses desivac, equipment needed for the technology and
Operating cost is high, and batch is limited, and the operating time is long, and tablet thickness about 1mm, bad mechanical strength is not amenable to common aluminum plastic packet
Dress.The present invention prepares olanzapine orally-disintegrating tablet using technique of direct powder compression, and technical process is simple, is produced using conventional tablet
Equipment can produce, at low cost, with short production cycle, and mechanical strength is good, and final product quality is stablized, and it is surprising that originally
It invents conventional tablet obtained and is but remarkably improved the dissolution rate of property drug hard to tolerate with a thickness of the thickness 3mm of conventional formulation,
Disintegration rate is even better than freeze-drying tablet.Preparation method processing step of the invention is simple, at low cost, consumes energy low, with short production cycle,
It is suitable for extensive promotion and application.
Specific embodiment
In order to better illustrate the present invention and its acquired effect, come furtherly below in conjunction with specific embodiment
It is bright.But the scope of the present invention is not limited to the concrete scheme of embodiment.
Embodiment 1:
Preparation: conventional tablet pharmaceutical equipment production can be used in the dosage form, and is prepared with direct tablet compressing technique, specific to prepare
Method is as follows: sieving with 100 mesh sieve main ingredient Olanzapine and aspartame are finely ground respectively, weighs recipe quantity, the two is uniformly mixed.It is micro-
Crystalline cellulose, crospovidone and mannitol cross 60 meshes respectively, weigh respectively according to quantity and sequentially add above-mentioned mix in order
It is mixed in composite medicine, the magnesium stearate of recipe quantity is then added, sieving mixes, and intermediates content detection is carried out, after determining slice weight
Using the tabletting of direct tablet compressing technology to get.
Embodiment 2:
Preparation: conventional tablet pharmaceutical equipment production can be used in the dosage form, and is prepared with direct tablet compressing technique, specific to prepare
Method is as follows: sieving with 100 mesh sieve main ingredient Olanzapine and aspartame are finely ground respectively, weighs recipe quantity, the two is uniformly mixed.It is micro-
Crystalline cellulose, crospovidone and mannitol cross 60 meshes respectively, weigh respectively according to quantity and sequentially add above-mentioned mix in order
It is mixed in composite medicine, the magnesium stearate of recipe quantity is then added, sieving mixes, and intermediates content detection is carried out, after determining slice weight
Using the tabletting of direct tablet compressing technology to get.
Embodiment 3:
Preparation: conventional tablet pharmaceutical equipment production can be used in the dosage form, and is prepared with direct tablet compressing technique, specific to prepare
Method is as follows: sieving with 100 mesh sieve main ingredient Olanzapine and aspartame are finely ground respectively, weighs recipe quantity, the two is uniformly mixed.It is micro-
Crystalline cellulose, crospovidone and mannitol cross 60 meshes respectively, weigh respectively according to quantity and sequentially add above-mentioned mix in order
It is mixed in composite medicine, the magnesium stearate of recipe quantity is then added, sieving mixes, and intermediates content detection is carried out, after determining slice weight
Using the tabletting of direct tablet compressing technology to get.
Embodiment 4:
Preparation: conventional tablet pharmaceutical equipment production can be used in the dosage form, and is prepared with direct tablet compressing technique, specific to prepare
Method is as follows: sieving with 100 mesh sieve main ingredient Olanzapine and aspartame are finely ground respectively, weighs recipe quantity, the two is uniformly mixed.It is micro-
Crystalline cellulose, crospovidone and mannitol cross 60 meshes respectively, weigh respectively according to quantity and sequentially add above-mentioned mix in order
It is mixed in composite medicine, the magnesium stearate of recipe quantity is then added, sieving mixes, and intermediates content detection is carried out, after determining slice weight
Using the tabletting of direct tablet compressing technology to get.
Embodiment 5:
Preparation: conventional tablet pharmaceutical equipment production can be used in the dosage form, and is prepared with direct tablet compressing technique, specific to prepare
Method is as follows: sieving with 100 mesh sieve main ingredient Olanzapine and aspartame are finely ground respectively, weighs recipe quantity, the two is uniformly mixed.It is micro-
Crystalline cellulose, crospovidone and mannitol cross 60 meshes respectively, weigh respectively according to quantity and sequentially add above-mentioned mix in order
It is mixed in composite medicine, the magnesium stearate of recipe quantity is then added, sieving mixes, and intermediates content detection is carried out, after determining slice weight
Using the tabletting of direct tablet compressing technology to get.
Embodiment 6:
Preparation: conventional tablet pharmaceutical equipment production can be used in the dosage form, and is prepared with direct tablet compressing technique, specific to prepare
Method is as follows: sieving with 100 mesh sieve main ingredient Olanzapine and aspartame are finely ground respectively, weighs recipe quantity, the two is uniformly mixed.It is micro-
Crystalline cellulose, crospovidone and mannitol cross 60 meshes respectively, weigh respectively according to quantity and sequentially add above-mentioned mix in order
It is mixed in composite medicine, the magnesium stearate of recipe quantity is then added, sieving mixes, and intermediates content detection is carried out, after determining slice weight
Using the tabletting of direct tablet compressing technology to get.
Experimental example 1, disintegration time mensuration
The disintegration time limited of each embodiment, friability, tablet hardness, the test bit of dissolution rate are as follows:
From the above-mentioned all data measured: using oral disintegrating tablet made from this method, disintegration time limited less than 10 seconds, firmly
Spend 3-5kg/cm2, less than 0.5%, 5min, the dissolution rate in 0.1N HCL solution is greater than 90% to friability.
Experimental example 2, compared with commercially available thin slice tablet disintegration time limit
The present invention is compared with commercially available closest to preparation disintegration effect, wherein comparative example composition are as follows:
The comparing result of disintegration time limited is as follows:
| Embodiment | Preparation thickness | Disintegration time limited |
| Embodiment 1 | 3mm | 8.6s |
| Embodiment 2 | 3mm | 7.5s |
| Embodiment 3 | 3mm | 5.3s |
| Embodiment 4 | 3mm | 7.2s |
| Embodiment 5 | 3mm | 6.5s |
| Embodiment 6 | 3mm | 7.8s |
| Comparative example | 1mm | 9.2s |
It can be seen that conventional tablet of the present invention from above-mentioned testing result and can reach close with sheet preparation and even preferably collapse
Solve speed.
Experimental example 3, factors influencing:
By embodiment 1, into embodiment 6, olanzapine tablet finished product is placed in surface plate, (opposite in high temperature (60 DEG C) high humidity
Humidity 92.5%) under the conditions of investigated, specifically, respectively by sample be placed in 60 DEG C of insulating boxs,
In the lighting box of 92.5% environment of relative humidity and 4500LX, each embodiment influence factor result is as follows:
Experimental example 4, compared with CN101904824 preparation disintegration time limited
Comparative example:
According to method described in CN101904824, inventor has carried out comparative test, and prescription is as follows:
Preparation: by Olanzapine, filler, adhesive, disintegrating agent, corrigent sieving mixing, being then added lubricant total mix,
Olanzapine orally-disintegrating tablet is made in final direct tablet compressing.
Disintegration time mensuration: taking this product 6, according to method (Chinese Pharmacopoeia 2010 under disintegration time limited detection method tablet item
Two Ⅹ A of annex of version) it checks, the time of block is not left using on mesh as the disintegration time of this product.
Experimental result: preparing resulting tablet when hardness is 3-5kg/cm2 according to CN101904824 experiment prescription,
Disintegration time limited is 28 seconds, and hardness is in 1-3kg/cm2When, disintegration time limited is 21 seconds, and friability is greater than 1%.
By above-mentioned experiment it is found that being disintegrated according to the resulting olanzapine orally-disintegrating tablet of CN101904824 and gained tablet of the present invention
Time limit significant difference, and olanzapine orally-disintegrating tablet is suitable for mental patient, disintegration rate is faster, and absorption is faster, therefore this hair
Bright products obtained therefrom has better curative effect to patient.
Note: the percentage of each component is weight percentage in invention formulation prescription.
Claims (3)
1. a kind of olanzapine orally-disintegrating tablet, which is characterized in that its disintegration time limited is less than or equal to 10 seconds,
It includes:
A) Olanzapine of 2% to 15% weight ratio；
B) mannitol of 20% to 78% weight ratio；
C) microcrystalline cellulose of 10% to 40% weight ratio；
D) crospovidone of 1% to 20% weight ratio；
E) aspartame of 0.2% to 5% weight ratio；With
F) magnesium stearate of 0.3% to 4% weight ratio；
50% partial size of the mannitol is lower than 100 μm, and 90% partial size is lower than 250 μm；50% partial size of the microcrystalline cellulose
Lower than 150 μm, 90% partial size is lower than 250 μm；50% partial size of the crospovidone is lower than 90 μm, and 90% partial size is lower than 150 μ
m。
2. olanzapine orally-disintegrating tablet according to claim 1, which is characterized in that it includes:
A) Olanzapine of 3% to 12% weight ratio；
B) mannitol of 25% to 78% weight ratio；
C) microcrystalline cellulose of 12% to 35% weight ratio；
D) crospovidone of 3% to 12% weight ratio；
E) aspartame of 0.2% to 2% weight ratio；With
F) magnesium stearate of 0.5% to 3% weight ratio.
3. a kind of method for preparing olanzapine orally-disintegrating tablet described in any one of -2 according to claim 1, which is characterized in that it is adopted
With technique of direct powder compression, specific steps are as follows:
1) main ingredient Olanzapine and aspartame difference is finely ground, it sieves with 100 mesh sieve, weighs recipe quantity, the two is uniformly mixed；
2) microcrystalline cellulose, crospovidone and mannitol are crossed into 60 meshes respectively, weighed respectively according to quantity, and is successively added in order
Enter in the hybrid medicine into step 1), mixes；
3) magnesium stearate of recipe quantity is added into hybrid medicine obtained in step 2), is sieved, mixes, carries out intermediates content
Detection, after determining slice weight, using the tabletting of direct tablet compressing technology to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310451237.7A CN104510717B (en) | 2013-09-27 | 2013-09-27 | Olanzapine orally-disintegrating tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310451237.7A CN104510717B (en) | 2013-09-27 | 2013-09-27 | Olanzapine orally-disintegrating tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104510717A CN104510717A (en) | 2015-04-15 |
| CN104510717B true CN104510717B (en) | 2019-02-05 |
Family
ID=52786956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310451237.7A Active CN104510717B (en) | 2013-09-27 | 2013-09-27 | Olanzapine orally-disintegrating tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104510717B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106389362A (en) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | Olanzapine orally disintegrating tablet and preparation method thereof |
| CN108261399A (en) * | 2016-12-30 | 2018-07-10 | 江苏豪森药业集团有限公司 | Olanzapine oral disnitegration tablet and preparation method thereof |
| CN108926543A (en) * | 2017-05-26 | 2018-12-04 | 万全万特制药江苏有限公司 | A kind of Olanzapine oral disnitegration tablet and preparation method thereof |
| CN108498472B (en) * | 2018-06-28 | 2021-03-16 | 苏州盛达药业有限公司 | Olanzapine tablet and preparation method thereof |
| CN113730365A (en) * | 2021-08-10 | 2021-12-03 | 杭州新诺华医药有限公司 | Olanzapine orally disintegrating tablet and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1681048A1 (en) * | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Orally disintegrating composition of olanzapine or donepezil |
| WO2006087629A2 (en) * | 2005-02-21 | 2006-08-24 | Aurobindo Pharma Limited | Rapidly disintegrating composition of olanzapine |
| CN101904824A (en) * | 2009-06-04 | 2010-12-08 | 齐鲁制药有限公司 | Olanzapine orally-disintegrating tablet preparation and preparation method thereof |
| CN102440974A (en) * | 2011-12-27 | 2012-05-09 | 天津市嵩锐医药科技有限公司 | Olanzapine orally disintegrating pharmaceutical composition |
| CN102499907A (en) * | 2011-11-02 | 2012-06-20 | 华裕(无锡)制药有限公司 | Orally disintegrating tablet composition |
| CN103142525A (en) * | 2013-03-21 | 2013-06-12 | 江苏豪森药业股份有限公司 | Olanzapine gastric soluble tablets and preparation method thereof |
-
2013
- 2013-09-27 CN CN201310451237.7A patent/CN104510717B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1681048A1 (en) * | 2005-01-14 | 2006-07-19 | Krka Tovarna Zdravil, D.D., Novo Mesto | Orally disintegrating composition of olanzapine or donepezil |
| WO2006087629A2 (en) * | 2005-02-21 | 2006-08-24 | Aurobindo Pharma Limited | Rapidly disintegrating composition of olanzapine |
| CN101904824A (en) * | 2009-06-04 | 2010-12-08 | 齐鲁制药有限公司 | Olanzapine orally-disintegrating tablet preparation and preparation method thereof |
| CN102499907A (en) * | 2011-11-02 | 2012-06-20 | 华裕(无锡)制药有限公司 | Orally disintegrating tablet composition |
| CN102440974A (en) * | 2011-12-27 | 2012-05-09 | 天津市嵩锐医药科技有限公司 | Olanzapine orally disintegrating pharmaceutical composition |
| CN103142525A (en) * | 2013-03-21 | 2013-06-12 | 江苏豪森药业股份有限公司 | Olanzapine gastric soluble tablets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 奥氮平口腔崩解片的制备及质量评价;封春香等;《医药前沿》;20120930;第84-85页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104510717A (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201815384A (en) | Tablet comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-benzaldehyde | |
| CN104510717B (en) | Olanzapine orally-disintegrating tablet and preparation method thereof | |
| TWI572360B (en) | Tiny cellulose powder | |
| CN104398481A (en) | Bilastine orally disintegrating tablet and preparing method thereof | |
| WO2011071139A1 (en) | Dry-coated orally disintegrating tablet | |
| TWI695722B (en) | Solid preparation outer layer composition and easy-to-take solid preparation containing the outer layer composition | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN108261399A (en) | Olanzapine oral disnitegration tablet and preparation method thereof | |
| JP2011026311A (en) | Method for producing tablet quickly disintegrating in oral cavity | |
| CN112585192A (en) | Cellulose powder, use thereof and tablet | |
| JP2007197373A (en) | Method for producing intraorally quickly disintegrating tablet | |
| JP6469234B2 (en) | Super-fast disintegrating tablet and method for producing the same | |
| CN102125524B (en) | Piracetam orally disintegrating tablets | |
| JP2021075686A (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
| WO2017047586A1 (en) | Tablet | |
| CN106038502A (en) | Ramelteon oral disintegrating tablets and preparation method thereof | |
| CN106511416A (en) | 3D printed radix notoginseng total saponins orally disintegrating tablet and preparation method thereof | |
| TW201636008A (en) | Very rapidly disintegrating tablet, and method for producing same | |
| JP6744517B1 (en) | Cellulose composition, tablet and orally disintegrating tablet | |
| CN102675338A (en) | Micronization prasugrel and medicinal composition of prasugrel | |
| CN107252418B (en) | A method of preparing oral fast disintegrating tablets for the treatment of hypokalemia by 3D printing technology | |
| CN114173767A (en) | Novel composition of ibuprofen and acetaminophen | |
| CN109700773A (en) | A kind of ticagrelor preparation compositions and preparation method thereof | |
| CN104337783B (en) | A kind of capecitabine tablet and preparation method thereof | |
| CN109512790A (en) | A kind of prescription and preparation process of oral disnitegration tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160318 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |